Idera Pharmaceuticals to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it will provide an overview of its Toll-like Receptor-targeted drug discovery and development programs and a general corporate update at the following conferences:

  • The Sixth Annual Noble Financial Capital Market’s Equity Conference on Tuesday, June 8 at 2:00 p.m. EDT at The Hard Rock Hotel in Hollywood, FL.
  • The Jefferies Global Life Sciences Conference on Friday, June 11 at 11:30 a.m. EDT at the Grand Hyatt Hotel in New York City.

The presentations will be available via live audio webcast on the Company’s website at www.iderapharma.com. Archived replays will also be located on the Company’s site following the events. Presentations dates and times are subject to change. The most up-to-date information will be available on the Company’s website.

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals develops drug candidates to treat infectious diseases, autoimmune and inflammatory diseases, cancer, and respiratory diseases, and for use as vaccine adjuvants. Our proprietary drug candidates are designed to modulate specific Toll-like Receptors, which are a family of immune system receptors that direct immune system responses. Our pioneering DNA and RNA chemistry expertise enables us to create drug candidates for internal development and generates opportunities for multiple collaborative alliances. For more information, visit www.iderapharma.com.

Idera Forward Looking Statements

This press release contains forward-looking statements concerning Idera Pharmaceuticals, Inc. that involve a number of risks and uncertainties. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words "believes," "anticipates," "plans," "expects," "estimates," "intends," "should," "could," "will," "may," and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause the Company’s actual results to differ materially from those indicated by such forward-looking statements, including whether products based on the Company’s technology will advance into or through the clinical trial process on a timely basis or at all and receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if the Company’s products receive approval, they will be successfully distributed and marketed; whether the Company’s cash resources will be sufficient to fund the its operations; and such other important factors as are set forth under the caption "Risk Factors" in the Company’s Quarterly Report on Form 10-Q for the three months ended March 31, 2010, which important factors are incorporated herein by reference. The Company disclaims any intention or obligation to update any forward-looking statements.



CONTACT:

Idera Pharmaceuticals, Inc.
Kelly Luethje, 617-679-5519
[email protected]
or
MacDougall Biomedical Communications
Chris Erdman, 781-235-3060
[email protected]ocom.com

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  General Health

MEDIA:

Logo
 Logo

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.